Investors put skin in Peninsula biotech’s psoriasis game, and it delivers results

Alumis is now armed with a half-billion in cash and a wide range of targets, starting with psoriasis.
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks